Last Price
40.41
Today's Change
+0.99 (2.51%)
Day's Change
39.23 - 40.48
Trading Volume
223,757
Market Cap
3 Billion
Shares Outstanding
75 Million
Avg Volume
365,562
Avg Price (50 Days)
39.99
Avg Price (200 Days)
42.08
PE Ratio
-14.80
EPS
-2.73
Earnings Announcement
06-Nov-2024
Previous Close
39.42
Open
39.58
Day's Range
39.23 - 40.48
Year Range
27.985 - 50.99
Trading Volume
280,964
1 Day Change
2.51%
5 Day Change
1.51%
1 Month Change
3.80%
3 Month Change
2.17%
6 Month Change
-4.76%
Ytd Change
-10.02%
1 Year Change
10.14%
3 Year Change
27.68%
5 Year Change
395.83%
10 Year Change
284.86%
Max Change
284.86%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.